|April 2006 · Vol. 18, No. 4
Progesterone gel for preterm prevention
I read Dr. Robert L. Barbieri’s editorial, “The pipeline runneth over” (January), with great interest. It’s nice to see some attention paid to drugs likely to be of use to gynecologists. I share Dr. Barbieri’s enthusiasm for this area of research.
Like Dr. Barbieri, I am concerned about the lack of development in the obstetric arena, with one glaring exception: Columbia Labs’ (Livingston, NJ) ongoing study of the vaginal progesterone gel, Prochieve, for the new indication of preventing preterm delivery. If the gel proves to be effective in the trial, it will be an important advance.